Proportion and Clinical Characteristics of Double‐Seronegative NMOSD in a Multicenter Real‐World Cohort
European Journal of Neurology · 2026-11 · 33 (11)
DOI: 10.1111/ene.70808 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Neurology, online erschienen am 03.11.2026. Verfasst von Jae-Won Hyun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Republic of Korea. Hauptthemen laut MEDLINE: Neuromyelitis Optica, Aquaporin 4. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Recent 2025 neuromyelitis optica spectrum disorder (NMOSD) criteria distinguish AQP4‐IgG‐positive disease from seronegative‐syndromic groups, into which double‐seronegative‐NMOSD (DN‐NMOSD) may be reclassified, suggesting the need to better characterize DN‐NMOSD within prior diagnostic frameworks.
Objective
To determine the proportion and clinical characteristics of DN‐NMOSD using rigorously applied 2015 NMOSD criteria with cell‐based assays (CBAs).
Methods
In this multicenter retrospective cohort study across four Korean referral centers, 634 individuals fulfilling the 2015 criteria were identified. AQP4‐IgG and MOG‐IgG were assessed using CBAs, with repeated testing in initially seronegative individuals.
Results
DN‐NMOSD accounted for 8.4% (53/634). Median onset age was 36 years, with mild female predominance (59%). At disease onset, classical NMO phenotype (simultaneous optic neuritis and myelitis) was rare (2%), and isolated brain involvement without myelitis, optic neuritis, or area postrema syndrome was uncommon (13%). Over a median 9‐year follow‐up, 93% showed a relapsing course, and maintenance immunosuppressive therapy was used in 91% with reduction in relapse rate after treatment ( p < 0.001).
Conclusions
In a large multicenter cohort, DN‐NMOSD represents a small proportion of NMOSD when stringent diagnostic criteria and repeated CBA testing are applied. These findings may provide data relevant to ongoing discussions on classification of the seronegative‐syndromic group within evolving diagnostic frameworks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Republic of Korea.
- Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Neurology, Chonnam National University Hospital and Medical School, Gwangju, Republic of Korea.
- Department of Neurology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
ORCID-Profile: Jae-Won Hyun, Ki Hoon Kim, Seung Woo Kim, Ha Young Shin, You-Ri Kang, Tai-Seung Nam, Woojun Kim, Su-Hyun Kim, Ho Jin Kim
Zitieren
APA
Hyun, J. W., Kim, K. H., Kim, S. W., Shin, H. Y., Kang, Y. R., Nam, T. S., Kim, W., Kim, S. H., & Kim, H. J. (2026). Proportion and Clinical Characteristics of Double‐Seronegative NMOSD in a Multicenter Real‐World Cohort. European Journal of Neurology, 33(11). https://doi.org/10.1111/ene.70808
Vancouver
Hyun JW, Kim KH, Kim SW, Shin HY, Kang YR, Nam TS, et al. Proportion and Clinical Characteristics of Double‐Seronegative NMOSD in a Multicenter Real‐World Cohort. European Journal of Neurology. 2026;33(11). doi:10.1111/ene.70808
BibTeX
@article{Hyun2026,
author = {Hyun, Jae-Won and Kim, Ki Hoon and Kim, Seung Woo and Shin, Ha Young and Kang, You-Ri and Nam, Tai-Seung and Kim, Woojun and Kim, Su-Hyun and Kim, Ho Jin},
title = {Proportion and Clinical Characteristics of Double‐Seronegative NMOSD in a Multicenter Real‐World Cohort},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {11},
doi = {10.1111/ene.70808}
}
EUVIMED